DIADEMA PARTNERS LP
Q3 2026 Form 13-F

MORRISTOWN, DELAWARE
CIK 0002026172 · CRD 331527 · SEC-registered investment adviser
$780.5M Reported Value Total

DIADEMA PARTNERS LP reports 7 total accounts under management (AUM). There are 7 discretionary accounts valued at $397,900,939, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
3 funds · $337.6M gross asset value
Hedge Fund: $337.6M
Source: Form ADV filed 2026-03-20
Reported value
$780.5M
Quarter over quarter
-2.6%
Holdings
81
Top-10 concentration
38.4%

Filing Structure

Holdings reported by

Key People

Form ADV owners & control persons
Timothy Beau Bassett
CHIEF INVESTMENT OFFICER, LIMITED PARTNER
Zachary Kayn Canonico
CHIEF OPERATING OFFICER, CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 16, 2026
Form 13F-HR
Reported value $780.5M
Positions 81
Change in reported value -1.4%
New positions 36
Exited positions 31
Position turnover 59.8%
Top-10 concentration 38.4%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
81 $780.5M
Q2 2026 13F
Filed Aug 14, 2026
77 $791.3M
Q1 2026 13F
Filed May 15, 2026
86 $587.7M
Q4 2025 13F
Filed Feb 17, 2026
73 $580.5M
Q3 2025 13F
Filed Nov 14, 2025
59 $391.0M
Q2 2025 13F
Filed Aug 14, 2025
46 $328.2M
Q1 2025 13F
Filed May 15, 2025
43 $383.3M
Q4 2024 13F
Filed Feb 14, 2025
54 $233.1M

Top 20 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 VKTX P VIKING THERAPEUTICS INC $44.4M 5.69%
2 BMY C BRISTOL-MYERS SQUIBB CO $37.4M 4.8%
3 VKTX C VIKING THERAPEUTICS INC $37.1M 4.76%
4 VKTX VIKING THERAPEUTICS INC $32.6M 4.18%
5 KOD P KODIAK SCIENCES INC $28.2M 3.61%
6 UTHR C UNITED THERAPEUTICS CORP DEL $25.7M 3.3%
7 UTHR UNITED THERAPEUTICS CORP DEL $25.0M 3.21%
8 BNTX C BIONTECH SE $24.6M 3.15%
9 KOD C KODIAK SCIENCES INC $23.9M 3.06%
10 BMY P BRISTOL-MYERS SQUIBB CO $20.6M 2.64%
11 COGT COGENT BIOSCIENCES INC $20.6M 2.63%
12 GMAB C GENMAB A/S $18.5M 2.37%
13 KYMR C KYMERA THERAPEUTICS INC $18.0M 2.3%
14 ABVX ABIVAX SA $17.7M 2.27%
15 BBIO 1.75 03/01/31 BRIDGEBIO PHARMA INC $16.5M 2.11%
16 SMMT C SUMMIT THERAPEUTICS INC $16.2M 2.08%
17 BMRN BIOMARIN PHARMACEUTICAL INC $15.3M 1.96%
18 RVMD REVOLUTION MEDICINES INC $14.4M 1.84%
19 NVS P NOVARTIS AG $14.3M 1.83%
20 VKTX VIKING THERAPEUTICS INC $14.1M 1.81%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Similar Managers

Finding Similar Managers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings